Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA30X in R/R CD19+ B-line Hematological Malignancies
NCT04689204Phase 1Completed
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cta-30x in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Dec 2020; status: completed.
02
Drugs
cta-30x
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04689204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689204.